Efficacy and Safety of Immunotherapy With Allogeneic Dendritic Cells, DCP-001, in Patients With Acute Myeloid Leukaemia (ADVANCE-II)

• ClinicalTrials.gov Identifier: NCT03697707
• Recruitment Status: Active, not recruiting
• First Posted: October 5, 2018
• Last Update Posted: October 10, 2022
• Sponsor: Mendus
• Collaborator: Amsterdam UMC, location VUmc
• Information provided by (Responsible Party): Mendus

Study Description

Brief Summary:

Phase II study to evaluate safety and efficacy of DCP-001 in patients with AML in CR, and with presence of MRD

Condition or disease	Intervention/treatment	Phase
Acute Myeloid Leukemia in Remission	Biological: DCP-001	Phase 2

Detailed Description:

International, multicentre, open-label proof of concept study exploring two different dose groups of the allogeneic dendritic cell vaccine, DCP-001. Cohort 1 consists of 10 patients that will receive 25E6 DCP-001 cells per vaccination and Cohort 2 consists of 10 patients who will receive 50E6 DCP-001 cells per vaccination. All patients will be given two additional booster vaccinations of 10E6 cells. Each patient will be followed up for 12 months after the 4th vaccination. Safety will be monitored throughout the study. Sera and cell samples (blood and bone marrow) will be collected for assessment of efficacy (MRD evaluation) and immune response monitoring.

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 20 participants
• Allocation: Non-Randomized
• Intervention Model: Sequential Assignment
• Intervention Model Description: First 10 patients will get the lowest dose and next 10 patients will receive the highest dose
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: An International, Multicentre, Open-label Study To Evaluate The Efficacy and Safety of Two Different Vaccination Regimens of Immunotherapy With Allogeneic Dendritic Cells, DCP-001, in Patients With Acute Myeloid Leukaemia That Are In Remission With Persistent MRD
• Actual Study Start Date: October 15, 2018
• Estimated Primary Completion Date: March 2023
• Estimated Study Completion Date: December 2025

Arms and Interventions

Arm	Intervention/treatment
Experimental: Cohort 1: Low dose; patients receiving 4 bi-weekly vaccinations with 25E6 cells/vaccination of DCP-001, and 2 booster vaccinations with 10E6 cells/vaccination	Biological: DCP-001; allogeneic dendritic cell vaccine
Experimental: Cohort 2: High dose; patients receiving 4 bi-weekly vaccinations with 50E6 cells/vaccination of DCP-001, and 2 booster vaccinations with 10E6 cells/vaccination	Biological: DCP-001; allogeneic dendritic cell vaccine

Outcome Measures

Primary Outcome Measures :

1. minimal residual disease (MRD) [ Time Frame: up to 32 weeks ]
   Any change in MRD (flow cytometric) as compared to baseline MRD

Secondary Outcome Measures :

1. Treatment emergent adverse events (TEAEs) [ Time Frame: up to 56 weeks ]
   adverse event
2. Serious Adverse Events (SAEs) [ Time Frame: up to 56 weeks ]
   adverse events
3. Relapse-free survival [ Time Frame: up to 56 weeks ]
   efficacy
4. Overall survival [ Time Frame: up to 56 weeks ]
   efficacy
5. Immune responses [ Time Frame: up to 32 weeks ]
   Any change in immunoreactivity (specific and non-specific) as compared to baseline

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

1. Confirmed diagnosis of AML according to WHO2016 criteria, including cytological, molecular and cytogenetic criteria (except acute pro-myelocytic leukaemia/APL).
2. In CR1 (first complete remission) or CRi (incomplete blood count recovery) documented by bone marrow examination up to one month before vaccination; CR defined as less than 5% blasts in normo-cellular bone marrow, ANC >1*E9/L, platelet count >100*E9/L, no evidence of extra-medullary disease. Patients in CRi (patients with <5% blasts but with incomplete blood count recovery) should have platelets >50 E9/L.
3. MRD as defined by multicolour flow cytometry (MFC) at a value of > 0.1%, or detection of specific molecular abnormalities such as NPM1 mutation.
4. Patients that are in CR1 or CRi. Patients not having undergone consolidation therapy must have been in CR1 for at least 1 month prior to enrolment. Patients treated with hypomethylating agents must have been given at least two cycles and up to a maximum of nine cycles of hypomethylating agents.
5. Expected and willing to undergo all study procedures, including outpatient evaluations for clinical and immunological monitoring.
6. Male or female of ≥ 18 years of age.
7. Women of childbearing potential must be using anti-conceptive therapy or use two (2) barrier contraceptive methods (one by each partner and at least one of the barrier methods must include spermicide (unless spermicide is not approved in the country or region). See section 12.7 for birth control methods deemed acceptable for this study.
8. ECOG (WHO) performance status 0-2.
9. Willing and able to provide written informed consent for participation in the study

Exclusion Criteria:

1. Acute Promyelocytic (APL; M3) type of AML.
2. Patients who have undergone or are scheduled/eligible for allogeneic stem cell transplantation.
3. History of previous allogeneic bone marrow or solid organ transplantation.
4. Uncontrolled or serious infections
5. Ongoing immunosuppressive therapy, other than short use of low dose steroids, i.e. equivalent to an average dose of ≤10mg of prednisone/day.
6. Chemotherapy and antineoplastic hormonal therapy within 28 days prior to the screening visit, with the exception of hypomethylating agents such as azacitidine and decitabine, or midostaurin for FLT3 mutations, or patients treated with IDH12 inhibitors in mIDH1/2.
7. Current or past medical history autoimmune disease.
8. Inadequate liver function (AST and ALT > 3 x ULN, serum bilirubin >3 x ULN).
9. Other active Malignancies within the last 5 years, except for adequately treated carcinoma in situ of the cervix or squamous carcinoma of the skin or adequately controlled limited basal cell skin cancer.
10. Pregnant or lactating females.
11. Major surgical procedure (including open biopsy) within 28 days prior to the first study treatment, or anticipation of the need for major surgery during the course of the study treatment.
12. Uncontrolled hypertension (systolic > 150 mm Hg and/or diastolic > 100 mm Hg) or clinically significant (i.e. active) cardiovascular disease.
13. Evidence of any other medical conditions (such as psychiatric illness, physical examination or laboratory findings) that may interfere with the planned treatment, affect patient compliance or place the patient at high risk from treatment-related complications.
14. Known HIV, Hepatitis B and/or Hepatitis C infections.
15. History of hypersensitivity to the investigational medicinal product or to any excipient present in the pharmaceutical form of the investigational medicinal product.

Contacts and Locations

Locations

Finland

Helsinki University Hospital

Helsinki, Finland

Germany

Universitats Klinikum Bonn

Bonn, Germany

Marien Hospital

Düsseldorf, Germany, D- 40479

Universitats Klinikum Leipzig

Leipzig, Germany

Universitätsmedizin Mainz

Mainz, Germany

Netherlands

VUmc

Amsterdam, Netherlands

UMCG

Groningen, Netherlands

Maastricht University Medical Centre

Maastricht, Netherlands

Norway

Haukeland universitetssjukehus

Bergen, Norway

Sweden

Uppsala University Hospital

Uppsala, Sweden

Sponsors and Collaborators

Mendus

Amsterdam UMC, location VUmc

Investigators

• Principal Investigator: A A van de Loosdrecht, MD, PhD; Amsterdam UMC, location VUmc

More Information

Publications:

van de Loosdrecht AA, van Wetering S, Santegoets SJAM, Singh SK, Eeltink CM, den Hartog Y, Koppes M, Kaspers J, Ossenkoppele GJ, Kruisbeek AM, de Gruijl TD. A novel allogeneic off-the-shelf dendritic cell vaccine for post-remission treatment of elderly patients with acute myeloid leukemia. Cancer Immunol Immunother. 2018 Oct;67(10):1505-1518. doi: 10.1007/s00262-018-2198-9. Epub 2018 Jul 23.

• Responsible Party: Mendus
• ClinicalTrials.gov Identifier: NCT03697707
• Other Study ID Numbers: DCOne-002
• First Posted: October 5, 2018
• Last Update Posted: October 10, 2022
• Last Verified: October 2022

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Mendus:

AML in CR1 or CRi; DCOne; DCP-001; Minimal Residual Disease

Additional relevant MeSH terms:

Leukemia; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Neoplasms by Histologic Type; Neoplasms